NZ610401A - Inhibitors of the mutant form of kit - Google Patents

Inhibitors of the mutant form of kit

Info

Publication number
NZ610401A
NZ610401A NZ610401A NZ61040104A NZ610401A NZ 610401 A NZ610401 A NZ 610401A NZ 610401 A NZ610401 A NZ 610401A NZ 61040104 A NZ61040104 A NZ 61040104A NZ 610401 A NZ610401 A NZ 610401A
Authority
NZ
New Zealand
Prior art keywords
kit
mutant form
dependent disease
inhibitors
midostaurin
Prior art date
Application number
NZ610401A
Inventor
Elisabeth Buchdunger
Doriano Fabbro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ610401A publication Critical patent/NZ610401A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Use of an inhibitor selected from midostaurin for manufacturing a drug for the treatment of a KIT dependent disease in a patient, wherein said KIT dependent disease is associated with a mutant form of KIT, and wherein: (a) the mutant form of KIT associated with the KIT dependent disease is identified as D816F, D816H, D816N, V654A, and T6701, that is associated with the KIT dependent disease selected from acute myelogenous leukemia, gastrointestinal stromal tumors, seminomas and dysgerminomas; and (b) the drug comprises an effective mutant KIT inhibiting amount of midostaurin.
NZ610401A 2003-11-18 2004-11-17 Inhibitors of the mutant form of kit NZ610401A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52071403P 2003-11-18 2003-11-18
NZ59633204 2004-11-17

Publications (1)

Publication Number Publication Date
NZ610401A true NZ610401A (en) 2014-08-29

Family

ID=51582133

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ610401A NZ610401A (en) 2003-11-18 2004-11-17 Inhibitors of the mutant form of kit

Country Status (1)

Country Link
NZ (1) NZ610401A (en)

Similar Documents

Publication Publication Date Title
UA93351C2 (en) Phthalazine derivatives as parp inhibitors
TW200612910A (en) Medicaments comprising carbonyl compounds, and the use thereof
BR0308243A (en) Compound, pharmaceutical formulation, and, methods of treating diabetes, alzheimer's disease, and inhibiting gsk-3 in a mammal
IS2517B (en) Use of substituted 2-aminotetralins in the prevention of Parkinson's disease
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
UA85707C2 (en) Benzoxazines for treating respiratory tract diseases
EA201000563A1 (en) TRIAZOLPYRIDINE INHIBITORS 11-BETA-HYDROXYSTEROID - DEHYDROGENASE TYPE I
MX2007003470A (en) Carbonyl compounds usable as coagulation factor xa inhibitors.
GEP20084391B (en) Pyrazoles and methods of making and using the same
WO2002034727A3 (en) Treatment of gastrointestinal stromal tumors
MX2007003104A (en) Novel phthalazinone derivatives, as aurora-a kinase inhibitors.
GB0402143D0 (en) Novel compounds
WO2007120333A3 (en) Tetracyclic kinase inhibitors
TW200628458A (en) Metasubstituted thiazolidinones, their manufacture and use as a drug
WO2003106450A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
SG139747A1 (en) Inhibitors of the mutant form of kit
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
BRPI0615141A2 (en) pentacyclic kinase inhibitors
TW200631584A (en) A medicament related to mirtazapine for the treatment of hot flush
GEP20094854B (en) Compounds for treating diseases of impaired gastric motility
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
GEP20094801B (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
GB0402138D0 (en) Novel compounds

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 17 NOV 2017 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20141210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2018 BY CPA GLOBAL

Effective date: 20171019

LAPS Patent lapsed